BOWEN DISEASE TREATMENT MARKET ANALYSIS

Bowen Disease Treatment Market, by Drug Type (Fluorouracil, Imiquimod, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Nov 2021
Code : CMI4791
Pages :152
Formats :
Excel and PDF
Industry : Pharmaceutical

Bowen Disease Treatment MarketSize and Trends

The global Bowen disease treatment market is estimated to be valued at US$ 356.5 million in 2021 and is expected to exhibit a CAGR of 4.5% over the forecast period (2021-2028).

Figure 1. Global Bowen Disease Treatment Market Share (%), By Region, 2021

The increasing incidence of squamous cell carcinoma in situ (Bowen disease) is expected to drive the growth of the global Bowen disease treatment market over the forecast period.

For instance, according to an article published by the JAMA Dermatology journal in July 2020, a study of 88,754 patients suffering from Bowen disease in Netherlands between January 1, 1989, and December 31, 2017 reveals that the incidence of Bowen disease (cutaneous squamous cell carcinoma in situ) had increased from 1989 to 2017 in Netherlands with the highest incidence of Bowen disease in 2017. The incidence rate was found to be 71.7 cases per 100,000 person-years in 2017 among women and 540.9 cases per 100,000 person-years among men.

The increasing research and development activities for the development of novel therapeutics for the treatment of Bowen disease is expected to drive the market growth over the forecast period.

For instance, in February 2021, Ponce Therapeutics, a U.S. based biotechnology company, announced the launch of its first research and development plan for the treatment of skin conditions such as Bowen disease, aging, and others. The company has hired its first scientists for executing its research and development plan. The research and development plan would majorly focus on p16 cell proliferation inhibitor, which is highly expressed in Bowen disease. This research and development plan would thus help in development of the company’s first product for regulatory approval as well as launch.

Market Trends

The global market for Bowen disease treatment is experiencing significant growth due to the increasing incidence of squamous cell carcinoma in situ (Bowen disease) which is driving market demand. With numerous clinical studies reinforcing the rising trend in the prevalence of Bowen disease, especially in regions like the Netherlands, the market is set to expand. Additionally, continuous research and development efforts aimed at discovering new therapeutic options contribute to this positive market outlook. The efforts by companies to launch novel research initiatives, such as those by Ponce Therapeutics that focus on targeted inhibitors like p16 cell proliferation, underline the proactive stance taken to address this public health concern. The coordinated approach between clinical research and practical drug development is anticipated to foster further market advancements and introduce new treatment paradigms that will likely shape future innovations in this field.